Immunomedics, Inc. (NASDAQ:IMMU)
A biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
sell on surges
Recs
Could show solid growth Sling'n them legal life savers and thrills.
Recs
There were 50 items in your list. Here they are in random order:
1 APOL 2S
CBPO (ALREADY PICKED)
2 AFAM 5S
3 IMMU 3*
4 TNDM 5*
AMED
RAI
VPHM
SNTS
CNU
SOLR
IDCC
HRB
UNTD
UEPS
CHKE
SOHU
DECK
OSK
PDLI
NSR
CBI
LO
CYTK
TTT
JCOM
MHP
CHOP
EME
RGR
CSKI
RTN
UIS
ENDP
PRSC
IPXL
VALU
USMO
ELNK
GME
FWLT
CF
ARO
TSRA
MRX
CBST
PPD
DLX
FLR
LIWA
Timestamp: 2010-05-25 19:32:44 UTC
Recs
Relative to its industry, it has a high earnings yield. Also, strong earnings per share growth is predicted this year.
Recs
drugs in pipeline
Recs
timeframe is a bit long here...i actually believe IMMU will see significant PPS increases about a year sooner but there will be big gains in that four year period overall. greatly situated in the sectors that will see obscene amounts of private and public cash thrown at it, specifically immunotherapy and cancer treatments.
Recs
adding to my position Any opinions?
Recs
Deep pipeline, promising lupus drug is a good indicator of potential.
Recs
There is a vast underreported and researched arm of health care - auto immune dieases and pain care. Plus factopr in "health care reform" mutant viruses running away with headlines, I think this will be one of the companies perking up into the limelight.
Recs
phase ii trials are a long long way away from late phase iii trials...its appears that HGSI might have gotten the lead on a monclonal SLE drug (HGSI might even get the green light and get fast tracked thru the FDA approval process and to market after this november when they release their data)...it seems that gsk might have actually lost out!!!
All this leaves IMMU in the dust...and one drug a company does not make, esp a drug to market coming in second
Recs
good technology
Recs
No longer using cash to fuel its Bunson burners and has promising results in the pipeline and a fast track approval for hPAM 4.
Recs
Immunomedics hPAM4 antibody for pancreatic cancer is under the radar, but nearly 50% of patients treated in the phase l trial are having good responses with tumors shrinking and the quality of life during and after treatment has been very good, unlike with most Chemo's. This could be a huge home run. The company has stated they have no intention to license this product out.
Also, UCB will be coming out with data for Epratuzumab in their dosing trials for SLE (lupus) where they are trying to find the right dose for the phase lll trials. Every trial done so far has shown Epratuzumab to have efficacy in SLE. Another sleeper.
Recs
IMMU has moved to profitability over the past two quarters primarily based on the Nycomed deal. They continue to report promising results on a number of other trials for treatments of different forms of cancer. Immunomedics good cash position should provide sufficient funding in the current economic environment. Finally, the company holds an impressive portfolio of patents which seem to be undervalued by the market.
Recs
This biotech firm has a portfolio of marketable auction securities that it is selling as opportunities arise; patents and favorable phase two and three tests for drugs that improve the efficacy and reduce the deleterious effects of cancer drugs. It is currently trading above $2.60, and brokerage analysts project that it will trade at $7 within a year. It does seem to be taking a long time for management to negotiate royalty deals with major drug companies, which are said to be interested.
Recs
why not biotechs great place to put money . the use little gasoline
Recs
will get fda approval
Recs
So far I like what I see from the current clinical trial data. Even though I think it will underperform for the next year or so, it looks like a good entry point as far as price of stock. Just because it will probably underperform the 500 does not mean that a profit can't be made. I am sure that as with any biopharm company it will be a rollercoaster ride so I will begin taking positions with "spare change" and build my position gradually.
With biopharm, I look at it as I do when going to Vagas or Biloxi, never take more then I am willing to loose and plan on playing till the plane leaves...............
Translation, never spend it all in one casino, spread it out, make it last, have fun and when the cherries line up, drive it like you stole it!
FOOL ON this one for sure or not?
POPS83
Recs
something good maybe
Recs
Great stuff coming down the pipe. Good buy out candidate.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 29 : 1 2 Next »